31.9 C
Friday, May 17, 2024

FDA to Approve Pfizer Biontech Covid-19 Vaccine for ages 12 – 15 soon

Official sources in the U.S Food and Drug Administration indicated that the administration is preparing to approve the Pfizer-Biontech vaccine against Coronavirus to be used for adolescents aged 12-15 years by early next week.

Pfizer specialists have indicated that there are high expectations of obtaining FDA approval because the vaccine has proven effective in producing strong antibody responses in 12-15 year olds in a previous clinical trial.

Write with us at HBC

And the use of the Pfizer vaccine has been previously approved for adolescents over the age of 16 years in the United States of America, and the Food and Drug Administration is still considering expanding permission to use the Corona vaccine for those between the ages of 12-15 years.

The specialists indicated that the approval of the use of the Covid-19 vaccine in adolescents under the age of 15 years is a reinforcing step in the vaccination campaign in the world, and it will help calm the fears of parents eager to protect their children from infection with the Coronavirus.

Moderna and Johnson & Johnson are also testing Coronavirus vaccines on the age group of 12-18 years, and it is expected that the data for the study will come from the experience of Moderna company soon.

Pfizer and Moderna have launched new clinical trials to test Coronavirus vaccines on children under the age of 11 years, as Companies expect to start vaccinating this group at the end of 2022.

HBC Editors
HBC Editorshttp://www.healthcarebusinessclub.com
HBC editors are a group of healthcare business professionals from diversified backgrounds. At HBC, we present the latest business news, tips, trending topics, interviews in healthcare business field, HBC editors are expanding day by day to cover most of the topics in the middle east and Africa, and other international regions.

Related Articles

Subscribe to our newsletter

Get notified about our latest news and articles. We are not spammy, we promise.

Latest Articles